(Q38284820)

1 September 2017

1 reference

title

Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety (English)

1 reference

1 September 2017

1 reference

1 reference

1 reference

6

Erminia Ridolo

1 reference

1 September 2017

Giorgio Walter Canonica

8

object named as

Giorgio Walter Canonica

1 reference

1 September 2017

Marco Caminati

1

1 reference

1 September 2017

Anna Rita Dama

2

1 reference

1 September 2017

Ivana Djuric

3

1 reference

1 September 2017

Marcello Montagni

4

1 reference

1 September 2017

Michele Schiappoli

5

1 reference

1 September 2017

Gianenrico Senna

7

1 reference

1 September 2017

6 December 2014

1 reference

Expert Review of Clinical Immunology

1 September 2017

1 reference

1 September 2017

11

1 reference

1 September 2017

2

1 reference

1 September 2017

233-245

1 reference

Allergen immunotherapy: a history of the first 100 years

1 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Anaphylaxis: still a ghost behind allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

GA² LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Allergen immunotherapy: a practice parameter third update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reactions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Specific immunotherapy in asthma: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Immunotherapy: clinical trials--optimal trial and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Fatalities from immunotherapy (IT) and skin testing (ST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

First European data from the network of severe allergic reactions (NORA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Allergy immunotherapy safety: location matters!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Improving the safety of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Immunotherapy safety: what have we learned from surveillance surveys?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Evaluation of near-fatal reactions to allergen immunotherapy injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Systemic reactions to immunotherapy: influence of composition and manufacturer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Patients on subcutaneous allergen immunotherapy are at risk of intramuscular injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

The risk and management of anaphylaxis in the setting of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Allergic rhinitis and asthma: celebrating 100 years of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

New directions in immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Safety evaluation of rapid build-up schedules with IR-standardized allergen extracts for subcutaneous immunotherapy of allergic respiratory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Accelerated immunotherapy schedules: review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Cluster protocols in SCIT: enough evidence for practical use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Systemic reactions to subcutaneous allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Safety of rush immunotherapy to multiple aeroallergens in an adult population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Safety of multiple aeroallergen rush immunotherapy using a modified schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Allergens of wild house dust mites: environmental Der p 1 and Der p 2 sequence polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Immunotherapy: what lies beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Aluminium in allergen-specific subcutaneous immunotherapy--a German perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Systemic reactions associated with subcutaneous allergen immunotherapy: timing and risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Arguing the misconceptions in allergen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Safety and tolerability of sublingual immunotherapy in clinical trials and real life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Local reactions during allergen immunotherapy do not require dose adjustment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2015.988143

10.1586/1744666X.2015.988143

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference